Array, Loxo to develop cancer drugs in potential $434M deal

Loxo Oncology and Array BioPharma agreed to co-develop the latter's preclinical drug candidate that targets an oncogenic activating mutation. The partners also agreed to collaborate in the discovery and development of small-molecule compounds against oncology targets chosen by Loxo. The deal entitles Array to as much $434 million in milestone fees plus sales royalties.

View Full Article in:

Daily Camera (Boulder, Colo.) · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL